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The solute carrier family 26, member 9 (SLC26A9) is an epithelial chloride channel that
is expressed in several organs affected in patients with cystic fibrosis (CF) including
the lungs, the pancreas, and the intestine. Emerging evidence suggests SLC26A9 as a
modulator of wild-type and mutant CFTR function, and as a potential alternative target to
circumvent the basic ion transport defect caused by deficient CFTR-mediated chloride
transport in CF. In this review, we summarize in vitro studies that revealed multifaceted
molecular and functional interactions between SLC26A9 and CFTR that may be
implicated in normal transepithelial chloride secretion in health, as well as impaired
chloride/fluid transport in CF. Further, we focus on recent genetic association studies
and investigations utilizing genetically modified mouse models that identified SLC26A9
as a disease modifier and supported an important role of this alternative chloride channel
in the pathophysiology of several organ manifestations in CF, as well as other chronic
lung diseases such as asthma and non-CF bronchiectasis. Collectively, these findings
and the overlapping endogenous expression with CFTR suggest SLC26A9 an attractive
novel therapeutic target that may be exploited to restore epithelial chloride secretion
in patients with CF irrespective of their CFTR genotype. In addition, pharmacological
activation of SLC26A9 may help to augment the effect of CFTR modulator therapies
in patients with CF carrying responsive mutations such as the most common disease-
causing mutation F508del-CFTR. However, future research and development including
the identification of compounds that activate SLC26A9-mediated chloride transport are
needed to explore this alternative chloride channel as a therapeutic target in CF and
potentially other muco-obstructive lung diseases.
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INTRODUCTION
Cystic fibrosis (CF) is a severe life-shortening multiorgan disease caused by mutations in the gene
encoding the CF transmembrane conductance regulator (CFTR) chloride channel, which plays a
fundamental role in salt and fluid transport across the surfaces and ducts of many epithelial organs
including the lungs, pancreas, and gastro-intestinal tract. In patients with CF, CFTR dysfunction
results in impaired epithelial ion and water transport that leads to a characteristic multi-organ
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pathology (Mall and Hartl, 2014). More, than 2000 CFTR variants
have been identified in CF patients, with F508del being the
most common accounting for 70% of all CF mutations (Sosnay
et al., 2013). Disease-causing mutations may lead to various
molecular defects in CFTR protein production, processing,
channel function, and stability at the plasma membrane (Welsh
and Smith, 1993; Mall and Hartl, 2014). Drug development
efforts aiming to restore CFTR function have yielded mutation
specific pharmacotherapies that are now available for a subgroup
of patients with CF (Gentzsch and Mall, 2018). These include
the CFTR potentiator compound ivacaftor (VX-770) that can
improve channel activity in CFTR gating mutations present
in ∼5% of CF patients and the combination of ivacaftor
with the CFTR corrector compound lumacaftor (VX-809) that
has been approved for F508del homozygous patients (Ratjen
et al., 2017). The large number of disease-causing variants and
the variability of biological effects of CFTR mutations and
their responsiveness to CFTR modulator therapies argues that
targeting an alternative chloride channel may be an attractive
therapeutic strategy in CF (Li et al., 2017). Emerging evidence
suggests that the alternative chloride channel SLC26A9 is a
modulator of CFTR function and a potential candidate to
circumvent the primary ion transport defect in several organs
affected by CF including the lungs, the pancreas, and the gastro-
intestinal tract independent of the CFTR genotype (Li et al., 2017;
Gentzsch and Mall, 2018). In this review, we summarize the
basic physiological and pharmacological properties of SLC26A9,
outline its regulation and molecular interaction with CFTR, detail
the role of SLC26A9 as a disease modifier in CF and potentially in
other diseases, and finally discuss the impact of these discoveries
on future research that is needed to explore this alternative




SLC26A9 is a member of the solute-linked carrier 26 (SLC26)
anion transporter family that functions uniquely as a chloride
channel with minimal conductance to bicarbonate (Dorwart
et al., 2007; Loriol et al., 2008). SLC26A9 is mainly expressed
in epithelial cells of the respiratory tract, stomach, duodenum,
ileum, and the pancreas, while transcripts were also detected in
the salivary gland, kidney, brain, heart, prostate, testis, ovary,
and skin (Lohi et al., 2002; Xu et al., 2005; Chang et al.,
2009b; Lee et al., 2015; Liu et al., 2015; Consortium, 2017).
SLC26 members share a conserved structural organization:
N-terminally the SLC26/sulphate permease transmembrane
domain and C-terminally the cytoplasmic sulphate transporter
and anti-sigma factor antagonist (STAS) domain (Geertsma
et al., 2015). The STAS domain plays a role in membrane
targeting, interaction with scaffolding proteins and other ion
channels (detailed later). Furthermore, structural variants in
the STAS domain were reported to associate with diseases
linked to SLC26 transporters (Sharma et al., 2011). SLC26A9
also has a type-I PDZ-binding domain at the C-terminus
(T-A-L), which may promote vesicular trafficking or assembly
of macromolecular complexes as seen in other SLC26 members
(Lohi et al., 2003; Rossmann et al., 2005). The human SLC26A9
transcript is alternatively spliced, such that inclusion of an
exon results in a 96 amino acid extension at the C-terminus
(isoform 2). The shorter splice form of 791 residues was
designated as canonical isoform, which was also mainly used
in heterologous expression systems; however, the isoform-ratio
in specific tissues has not yet been elucidated. Similarly to the
glycosylation pattern of CFTR, SLC26A9 also displays both core-
and complex N-glycosylated forms, which may be important
for plasma membrane targeting or function (Li J. et al., 2014;
Salomon et al., 2016; Thomson et al., 2016; Bertrand et al.,
2017).
The function of SLC26A9 has been widely investigated in
heterologous expression systems. Whole-cell patch clamp studies
showed that SLC26A9 is a constitutively active chloride channel
displaying linear current–voltage characteristics (Dorwart et al.,
2007; Loriol et al., 2008; Bertrand et al., 2009; Avella
et al., 2011b; Salomon et al., 2016), while the current
amplitude was not affected by cAMP stimulation or increase
in intracellular Ca2+ (Bertrand et al., 2009; Salomon et al.,
2016). Interestingly, SLC26A9-expressing epithelial monolayers
studied in Ussing chambers displayed constitutive and forskolin
stimulated chloride currents, which may be attributed to the
enhanced transepithelial electrochemical gradient generated by
activation of basolateral potassium channels by cAMP/PKA
signaling (Mall et al., 2000; Salomon et al., 2016). Moreover,
studies in primary human bronchial epithelial (HBE) cells
elegantly demonstrated the presence of a SLC26A9-mediated
transepithelial chloride conductance, which contributed to basal
and to cAMP/PKA stimulated chloride currents (Bertrand
et al., 2009, 2017). These finding support that SLC26A9
could provide an alternative pathway for chloride secretion
that may compensate for CFTR dysfunction in CF epithelia.
In addition, several studies suggested that SLC26A9 also
functions as a chloride-bicarbonate exchanger (Xu et al., 2005;
Chang et al., 2009b; Demitrack et al., 2010) and sodium
transporter (Chang et al., 2009b). However, the contribution
of SLC26A9 to epithelial bicarbonate and sodium transport is
not completely understood (see discussion at stomach) and it
is possible that transport modes depend on the cell and tissue
context.
In the absence of sensitive and specific antibodies for
immunolocalization studies, investigations of SLC26A9 largely
relied on pharmacological tools. Multiple compounds were
found to inhibit SLC26A9 at various potency and selectivity.
Highly effective inhibitors include several non-selective chloride
channel blockers, such as flufenamic acid, niflumic acid, GlyH-
101, and 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB),
while anion-exchanger inhibitor 4,4′-Diisothiocyanatostilbene-
2,2′-disulfonic acid (DIDS) only partially inhibited SLC26A9
(Dorwart et al., 2007; Loriol et al., 2008; Salomon et al., 2016).
On the other hand, SLC26A9 is not sensitive to diphenylamine-
2-carboxylic acid (DPC), glibenclamide or CFTRinh172,
which makes differentiation from CFTR-mediated chloride
currents possible (Loriol et al., 2008; Bertrand et al., 2009;
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Salomon et al., 2016). Despite the lack of highly selective
inhibitors, this characteristic “pharmacological fingerprint”
enabled investigation of SLC26A9-mediated chloride secretion in
primary epithelial cultures and native tissues (Anagnostopoulou
et al., 2012; Bertrand et al., 2017).
The constitutive channel activity suggests that SLC26A9-
mediated chloride secretion is controlled by the insertion and
stability of SLC26A9 channels in the plasma membrane. Previous
studies demonstrated that SLC26A9 cell surface expression is
influenced by WNK (with no lysine [K]) kinases that have
been implicated in the regulation of cell volume homeostasis
and ion transport processes in epithelial cells (Dorwart et al.,
2007; Salomon et al., 2016). WNK kinases uniquely function
as intracellular chloride and/or osmolality sensors that activate
downstream kinases serine/threonine-protein kinase 39 (SPAK)
and oxidative stress-responsive 1 protein (OSR1), which can
directly modulate ion transporters by phosphorylation (Alessi
et al., 2014; Bazúa-Valenti et al., 2015). Furthermore, WNKs
can also act as scaffolds that recruit other proteins that regulate
the activity or plasma membrane abundance of ion channels
(Rodan and Jenny, 2017). This kinase-independent function
of WNKs has been demonstrated to affect plasma membrane
trafficking of SLC26A9, as well as CFTR, by mechanisms that
may involve lysosomal targeting or endosomal sorting (Dorwart
et al., 2007; He et al., 2007; Yang et al., 2007; Zhou et al.,
2010).
Notably, there is a large overlap in the expression pattern of
SLC26A9 and CFTR in epithelial tissues and emerging evidence
suggests a complex, multifaceted interaction between the two
channels, both under physiological and pathophysiological
conditions. First, there is a functional interaction between the
two channels mediated by the STAS domain of SLC26A9 and
the R domain of CFTR. Although an inhibitory relationship
has also been suggested (Chang et al., 2009a), the nature of
this molecular interaction is likely stimulatory, as SLC26A9
contributes to cAMP-stimulated chloride currents in HBE
cells and co-expression of CFTR with SLC26A9 results in
larger chloride currents than expression of CFTR alone
(Loriol et al., 2008; Avella et al., 2011b). Interestingly,
the cellular background and level of differentiation may
be important determinants of this functional interaction
between SLC26A9 and CFTR, as suggested by a study that
showed a different behavior in human embryonic kidney
(HEK293) cells compared to polarized airway epithelial cells
(Ousingsawat et al., 2012). Of note, opposite functional
interactions between CFTR and SLC26A9 were also reported
in two heterologous expression studies that both used HEK
cells (Bertrand et al., 2009; Ousingsawat et al., 2012). While
these conflicting results are more difficult to reconcile, we
speculate that the observed differences in CFTR/SLC26A9
interactions may be related to differences in the cellular
background of the HEK cell clones used in the different
laboratories.
Biochemical and functional studies of two other SLC26 family
members, SLC26A6 and SLC26A3, showed that following cAMP-
dependent stimulation, the phosphorylated R domain can bind to
STAS domain, which leads to mutual activation of both CFTR
and SLC26 transporters (Ko et al., 2004). Coding mutations
located in the STAS domain of SLC26A9 may disrupt this
stimulatory interaction, as demonstrated by functional analysis
of variant L683P (Avella et al., 2011a). Interestingly, STAS
domain variant V622L and domain adjacent variant V744M
decreased chloride currents of SLC26A9, which could be partially
attributed to decreased plasma membrane expression (Chen
et al., 2012). Although no disease-association has been reported
for the variants above, these studies demonstrate the role of
SLC26A9 STAS domain in protein expression, channel function,
and stimulation of CFTR currents.
Second, a recent study demonstrated a physical interaction
between SLC26A9 and CFTR, which is mediated by PDZ
proteins that facilitate trafficking and stabilization of both
proteins at the cell surface (Bertrand et al., 2017). As shown by
co-localization studies, this interaction is not restricted to
the plasma membrane suggesting a common regulatory
mechanism along the secretory pathway (Avella et al.,
2011b; Bertrand et al., 2017). SLC26A9 shows affinity to
a number of PDZ proteins, such as Na+/H+ exchanger-3
regulatory factor 1 (NHERF1) and CFTR-associated ligand
(CAL), which display antagonistic effects in CFTR trafficking
(Bertrand et al., 2017). CAL, also known as GOPC (Golgi-
associated PDZ and coiled-coil motif-containing protein)
facilitates ubiquitination and lysosomal degradation of
CFTR, as well as endoplasmic reticulum (ER)-associated
degradation of F508del-CFTR, whereas NHERF1 tethers
CFTR to the plasma membrane thus promoting its cell
surface expression (Cheng and Guggino, 2013; Bergbower
et al., 2018). Moreover, F508del-CFTR could be rescued by
NHERF1 overexpression or CAL silencing (Wolde et al.,
2007; Castellani et al., 2012). Constitutive SLC26A9-mediated
chloride secretion is diminished in human bronchial epithelium
from CF donors carrying F508del-CFTR and recent evidence
suggests a PDZ-domain sensitive, CAL-dependent underlying
mechanism (Bertrand et al., 2009, 2017). Due to proteasomal
degradation of F508del-CFTR, association of CAL with
SLC26A9 increases, which in turn hampers its forward
trafficking. Furthermore, restoration of F508del-CFTR by
the small molecule CFTR corrector compound VX-809 increased
CFTR as well as SLC26A9 cell surface expression indicating
that rescue of intracellular processing of CFTR has a positive
influence on SLC26A9 membrane targeting. Consistent with
this notion, SLC26A9-mediated chloride currents were not
affected by co-expression with the CFTR gating mutation
G551D, which is inserted into the plasma membrane, but has
impaired CFTR chloride channel regulation (Bertrand et al.,
2017).
Third, numerous genetic association studies and
investigations utilizing genetically modified mouse models
supported an important role of SLC26A9 in the pathophysiology
of several organ manifestations in CF, as well as other chronic
lung diseases such as asthma and non-CF bronchiectasis
(Anagnostopoulou et al., 2012; Sun et al., 2012; Bakouh et al.,
2013; Blackman et al., 2013; Miller et al., 2015; Strug et al., 2016).
The results of these studies are consistent with an important role
of SLC26A9 as a disease modifier in CF and potentially other
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FIGURE 1 | SLC26A9 is a modifier of disease severity in multiple organs affected by CF. Graphical summary depicting associations of variants in SLC26A9 with
exocrine pancreatic insufficiency, CF-related diabetes mellitus (CFRD) and meconium ileus, and emerging data supporting a role of SLC26A9 as modifier of response
to CFTR modulator therapy in patients with CF. Beyond CF, SLC26A9 has been implicated in the pathogenesis of asthma, diffuse bronchiectasis (DB), and impaired
gastric acid secretion.
muco-obstructive lung diseases and are discussed in more detail
below (Figure 1).
SLC26A9 CHLORIDE CHANNEL AS A
DISEASE MODIFIER IN CF
Lung
Muco-obstructive lung disease remains the major cause of
morbidity and mortality in patients with CF. The basic CF ion
transport defect causes airway surface dehydration, impaired
mucociliary clearance and mucus obstruction, which triggers
chronic inflammation and infection, and ultimately leads to
progressive lung damage (Button et al., 2016). There is a large
heterogeneity in lung disease severity among CF patients, which
is influenced by genetic and environmental factors. It is estimated
that ∼50% of the genetically determined variability can be
attributed to the CFTR genotype and the other ∼50% to CF
modifier genes (Cutting, 2015). In an effort to identify genetic
determinants of CF lung disease, genome-wide association
studies (GWAS) were performed in large CF patient cohorts
(Wright et al., 2011; Corvol et al., 2015). These studies revealed
a number of loci and candidate genes that may influence
lung function, but initially, these investigations did not find
association with SLC26A9. However, more recently, SLC26A9
was reported as a modifier of lung function and response to
CFTR modulator therapy in patients carrying the CFTR gating
mutation G551D (Strug et al., 2016). In a cohort of over 1,700
F508del homozygous CF patients and 70 patients with at least
one G551D allele the authors examined the effect of SLC26A9
SNP rs7512462, which was previously reported to associate with
CF related diabetes, pancreatic insufficiency and meconium ileus.
The minor C allele of rs7512462 positively influenced lung
function in G551D CF patients, but had no effect in F508del
homozygotes. Furthermore, improvement of lung function, as
determined from FEV1 response to therapy with the small
molecule CFTR potentiator ivacaftor (VX-770) was markedly
higher in patients carrying at least one protective C allele. This
study also assessed the effect of rs7512462 in primary HBE
cultures from F508del homozygous CF patients and found that
rescue of cAMP-stimulated currents in cultures pretreated with
lumacaftor (VX-809) increased with each additional C allele
(Strug et al., 2016). In the presence of an in vitro modulatory
effect, the lack of SLC26A9 association with lung function
in F508del homozygous patients is difficult to reconcile. One
explanation may entail the F508del dependent trafficking defect
of SLC26A9 and the necessity of CFTR plasma membrane
targeting for SLC26A9 function discussed above (Bertrand et al.,
2017). On the other hand, age-dependent expression may also be
involved. Interestingly, a recent study in a Brazilian cohort of
188 CF patients revealed association of rs7512462 with several
outcome measures of pulmonary function (Pereira et al., 2017).
Taken together, these data support that SLC26A9 is a modulator
of response to CFTR targeted therapies, which in the future may
help predict patient outcomes and optimize tailored treatment
regimens for individual patients with CF.
Idiopathic diffuse bronchiectasis (DB) is a chronic lung disease
involving airway mucus obstruction, recurrent infections, airway
inflammation, and remodeling that resembles CF lung disease in
many aspects (Bergougnoux et al., 2015). Interestingly, a previous
study reported rare loss-of-function SLC26A9 mutations in
patients with DB suggesting that SLC26A9 may be implicated in
disease pathogenesis. In a study comparing 147 patients with DB,
78 patients with CF and 50 healthy controls, exon sequencing
of SLC26A9 revealed coding variants R575Y and V486I in two
DB patients (Bakouh et al., 2013). Functional analysis showed
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that both mutations abolished chloride currents and that R575Y
located in the STAS domain also interfered with the stimulatory
interaction with CFTR.
Further insights on the importance of SLC26A9 in airway
epithelial chloride secretion, airway surface hydration, and
mucus clearance came from studies in mice with allergic airway
disease. In a murine model of allergic asthma, it was shown
that type 2 airway inflammation induced SLC26A9-mediated Cl−
secretion, which prevented airway mucus plugging in presence
of mucus hypersecretion (Anagnostopoulou et al., 2010, 2012).
In the absence of allergic airway inflammation, Slc26a9-deficient
(Slc26a9−/−) mice displayed normal lung morphology and no
differences in epithelial ion transport when compared to wild-
type mice. However, in the presence of allergic inflammation
Slc26a9−/− mice lacked upregulation of chloride secretion
and mucus hypersecretion led to airway mucus plugging.
Furthermore, three SNPs at 3′ UTR of SLC26A9 were identified
that were associated with a risk for childhood asthma, with
an odds ratio of 1.48. Functional investigations revealed that
one of these non-coding variants altered a putative micro-RNA
response element in the 3′ UTR of SLC26A9 and lead to micro-
RNA mediated translational repression in vitro, indicating that
decreased SLC26A9 protein expression may be the underlying
mechanism for disease association (Anagnostopoulou et al.,
2012).
Stomach
Investigations in the stomach revealed an essential role of
SLC26A9 in the regulation of gastric acid secretion. In the gastric
mucosa SLC26A9 is expressed in the surface epithelial cells
and in the parietal cells of the deep gastric gland. Slc26a9−/−
mice displayed structural and ultrastructural changes, such as
distended gastric glands, hypoplasia of parietal cells, and loss
of tubulovesicular system inside the parietal cells (Xu et al.,
2008). Furthermore, H-K-ATPase expression was decreased.
Slc26a9−/− mice had complete achlorhydria, which could be
explained by the absence of transmucosal chloride secretion
and/or the role of Slc26a9 in the maintenance and maturation of
the secretory pathway that regulates the H-K-ATPase trafficking.
Alternatively, Slc26a9 could also promote gastric bicarbonate
secretion and regulation of luminal pH to protect against injury
by gastric acid (Xu et al., 2005; Demitrack et al., 2010). It is
currently debated how SLC26A9 could contribute to bicarbonate
secretion. One possibility would be that SLC26A9-mediated
chloride secretion is paralleled by chloride-bicarbonate exchange
via apical anion exchangers, similarly to the proposed model
of pancreatic fluid secretion, where CFTR works tandem with
anion exchangers to secrete bicarbonate (Stewart et al., 2009).
The second possibility is that SLC26A9 itself can operate
as an anion exchanger, which was supported by two studies
on gastric epithelium (Xu et al., 2005; Demitrack et al.,
2010), however, most heterologous expression data suggest that
SLC26A9 functions as an ion channel with minimal bicarbonate
conductance. Third, the channel conductance to bicarbonate
could also be modulated, similarly to the regulation of CFTR
bicarbonate permeability by WNK1-OSR1/SPAK pathway (Park
et al., 2010). Notably, SLC26A9 expression was upregulated
in Helicobacter pylori infection, as well as upon chronic
gastritis induced by interleukin-11 in mice, indicating that
SLC26A9 is a key player in gastric mucosal defense under
pathological conditions (Henriksnäs et al., 2006; Howlett et al.,
2012).
Intestine
Obstruction of the ileum due to highly viscous and sticky
bowel content, also known as meconium ileus, affects ∼15%
of newborns with CF. Sibling and twin studies demonstrated
a high heritability for this disease phenotype and a number of
genetic studies reported association of SLC26A9 with meconium
ileus (Blackman et al., 2006; Sun et al., 2012; Li W. et al., 2014;
Miller et al., 2015). SLC26A9 expression decreases along the
GI tract with relatively high levels in the stomach, medium
levels in the proximal duodenum, low levels in the ileum
and no detectable expression in the colon, whereas CFTR
shows an inverse pattern with low expression in the stomach
and high levels in the duodenum, small intestine and colon
(Liu et al., 2015). Cftr-deficient (Cftr−/−) mice show a severe
meconium ileus-like intestinal phenotype characterized by severe
intestinal plugging. When Cftr−/− mice were crossbred with
Slc26a9−/− mice, mortality highly increased, indicating that
SLC26A9-mediated anion secretion ameliorates meconium ileus
(Liu et al., 2015). Slc26a9−/− mice also failed to elicit duodenal
bicarbonate secretion in response to acid load, which may signify
the physiological role of SLC26A9 to neutralize gastric acid in the
duodenum (Singh et al., 2013).
Pancreas
Exocrine pancreatic insufficiency (PI) in CF is present from
early life in nearly all patients with severe CFTR genotypes.
CFTR is expressed in the pancreatic ductal epithelium and
regulates the secretion of an alkaline, bicarbonate rich pancreatic
fluid that washes out digestive enzymes produced by acinar
cells. CFTR dysfunction leads to an acidic, low volume, protein
rich secretion that can slow down or even block the outflow
of zymogens from the ductal tree (Kopelman et al., 1988).
Early histopathological changes include dilatation of ducts filled
with inspissated zymogen material and destruction of acinar
cells (Tucker et al., 2003). In advanced stages, fibrotic and
adipose tissue replaces acinar mass and destroys Langerhans-
islands (Gibson-Corley et al., 2016). PI shows a strong, but
incomplete correlation with CF genotype and CFTR chloride
channel function, while SLC26A9 can largely explain the
remainder of genetic variability (Cystic Fibrosis Genotype-
Phenotype Consortium, 1993; Hirtz et al., 2004; Li W. et al.,
2014; Miller et al., 2015). These studies found correlation
between circulating levels of immunoreactive trypsinogen (IRT),
an early biomarker for exocrine damage, and SLC26A9 SNPs
that also associated with meconium ileus and CF-related diabetes
mellitus (CFRD). The physiological function of SLC26A9 in
the pancreas is largely unexplored. Emerging data suggest that
SLC26A9 may enhance ductal anion transport and fluid secretion
(Li et al., 2016). Impaired SLC26A9-mediated secretion may
thus aggravate the defective ductal wash-out mechanism and
ductal plugging in CF. Reduced fluid secretion and ductal
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FIGURE 2 | Role SLC26A9 in healthy airways and as a therapeutic target in cystic fibrosis (CF). Healthy airway epithelia express SLC26A9 and CFTR that are
co-trafficked from the ER to the plasma membrane, where SLC26A9 functions as a constitutive and CFTR as a cAMP/PKA-regulated chloride channel. Further,
SLC26A9 and CFTR interact reciprocally to augment transepithelial chloride/fluid secretion essential to maintain proper airway surface hydration and effective
mucociliary clearance (A). In airway epithelial cells from patients with CF carrying the most common disease-causing mutation F508del-CFTR, impaired folding of
F508del leads to its retention in the ER and degradation by the proteasome. The F508del trafficking defect also hampers co-trafficking of SLC26A9 and its insertion
into the plasma membrane. Lack of SLC26A9 chloride channels may aggravate deficient chloride secretion in CF (B). Pharmacological rescue of F508del-CFTR
trafficking with the CFTR corrector lumacaftor (VX-809) restores co-trafficking and insertion of SLC26A9 chloride channels into the apical plasma membrane (C).
Compounds that facilitate trafficking of SLC26A9 in the absence of CFTR may improve chloride secretion and airway surface hydration in all patients with CF
regardless of the type of CFTR mutation. Alternatively, chloride secretion may also be facilitated by compounds that potentiate SLC26A9 channels that are present
and/or newly trafficked to the plasma membrane (D).
mucus obstruction are also present in chronic pancreatitis, a
disease that shares many key pathogenic features with CF of
the pancreas (Maléth et al., 2015; Balázs et al., 2018). It is
conceivable that SLC26A9 may also act as a modifier in these
disorders.
Pancreatic insufficiency confers a major risk for CFRD. CFRD
is an age-dependent complication that affects 2% of children and
50% of adults with high heritability (Blackman et al., 2009; Moran
et al., 2009). A GWAS identified major association of SLC26A9
variants with CFRD, with a hazards ratio of 1.47. Interestingly,
meta-analysis of two GWAS studies in type II diabetes showed
evidence for association with the same SLC26A9 SNPs, although
the risk allele was different (Blackman et al., 2013). There are
two prevailing hypotheses on CFRD development: one is that
CFRD is driven by the exocrine damage that stresses endocrine
cells and causes islet remodeling (Rotti et al., 2018). This
is supported by a Mendelian randomization study utilizing a
disease-associated SLC26A9 SNP, where a causal relationship
between PI and CFRD risk was determined (Soave et al., 2014).
Alternatively, loss of CFTR function might have a direct role in
insulin secretion (Guo et al., 2014) and/or result in an intrinsic
defect that impairs endocrine function before acinar damage
occurs (Gibson-Corley et al., 2016). Given its function as chloride
channel, it is possible that SLC26A9 may regulate membrane
potential and insulin secretion in β-cells, however, there are




In summary, SLC26A9 constitutes an alternative chloride
channel that is implicated in coordinated ion and fluid secretion
in various epithelial tissues affected in CF including the airways,
the pancreas and the gastro-intestinal tract (Lohi et al., 2002;
Dorwart et al., 2007; Bertrand et al., 2009). Demonstration of its
role as a disease modifier, as well as overlapping expression of
SLC26A9 and CFTR in several affected organs, suggest SLC26A9
as an attractive alternative therapeutic target to bypass the
primary ion transport defect in CF (Sun et al., 2012; Blackman
et al., 2013; Miller et al., 2015; Strug et al., 2016). In the
airways, activation of SLC26A9-mediated chloride/fluid secretion
is predicted to counteract airway surface dehydration that sets
the stage for mucus plugging and mucociliary dysfunction
and constitutes an important disease mechanism in CF lung
disease (Mall and Hartl, 2014). Similarly, in the gastro-intestinal
tract, activation of SLC26A9 chloride channels is expected
to improve the hydration of intestinal surfaces and facilitate
pancreatic fluid secretion thus counteracting important extra-
pulmonary organ dysfunctions in CF. Therefore, SLC26A9 is an
attractive target not only for the treatment of CF lung disease,
but also for systemic therapy that may be beneficial for the
prevention and/or treatment of several extrapulmonary disease
manifestations including meconium ileus and distal intestinal
obstruction syndrome (DIOS), exocrine pancreatic insufficiency
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and CFRD. Further, pharmacological activation of SLC26A9-
mediated chloride/fluid secretion may also be beneficial in
other muco-obstructive lung diseases and in chronic pancreatitis
(Mall, 2016; Balázs et al., 2018). Importantly activation of
an alternative chloride channel is expected to be beneficial
for all patients with CF, irrespective of their CFTR genotype,
including patients with non-sense or splicing mutations, where
no CFTR protein is made, or other rare CFTR mutations
that do not respond to emerging CFTR modulator therapies
(Li et al., 2017). Given the reciprocal interaction with CFTR
(Figures 2A–C), pharmacological activation of SLC26A9 may
also augment functional rescue of mutant CFTR achieved
by CFTR modulator therapies (Strug et al., 2016; Bertrand
et al., 2017). However, to date, no compounds that activate
SLC26A9 chloride channel function have been reported and
the development of such SLC26A9 modulators remains a major
challenge for further testing of these concepts in preclinical
models and in the clinical arena. In this context, the negative
impact of the common CFTR mutation F508del present on at
least one allele in ∼90% of CF patients on SLC26A9 trafficking
indicates that an ideal SLC26A9 modulator compound should
overcome this interaction and facilitate trafficking of SLC26A9
from the ER to the plasma membrane independent of CFTR
co-trafficking (Strug et al., 2016; Bertrand et al., 2017; Figure 2D).
In addition to compounds that facilitate SLC26A9 trafficking to
increase the number of channels, SLC26A9-mediated chloride
secretion may be augmented by compounds that enhance the
open probability of the channel or its stability in the plasma
membrane. Single channel recordings demonstrated SLC26A9
channels with open and closed states and a conductance of
∼3.2 pS (Chang et al., 2009b) suggesting that it may be
possible to increase the open probability by SLC26A9 potentiator
compounds. Taking the development of CFTR modulators as
a model for drug development, such SCL26A9 modulators
may be identified by high-throughput screening of compound
libraries in SLC26A9-expression epithelial cells (Gentzsch and
Mall, 2018). In addition, a better understanding of SLC26A9
regulation in epithelial tissues, including its interaction network
and signaling pathways, may help to explore SLC26A9 as a novel
therapeutic target in CF and potentially other muco-obstructive
lung diseases.
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